- Home
- ICHR vs AUPH Comparison
ICHR vs AUPH Comparison
Compare ICHR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICHR
- AUPH
- Stock Information
- Founded
- ICHR 1999
- AUPH 1993
- Country
- ICHR United States
- AUPH Canada
- Employees
- ICHR N/A
- AUPH N/A
- Industry
- ICHR Semiconductors
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ICHR Technology
- AUPH Health Care
- Exchange
- ICHR Nasdaq
- AUPH Nasdaq
- Market Cap
- ICHR 727.6M
- AUPH 1.1B
- IPO Year
- ICHR 2016
- AUPH 1999
- Fundamental
- Price
- ICHR $22.90
- AUPH $9.04
- Analyst Decision
- ICHR Strong Buy
- AUPH Strong Buy
- Analyst Count
- ICHR 6
- AUPH 2
- Target Price
- ICHR $33.60
- AUPH $11.50
- AVG Volume (30 Days)
- ICHR 408.2K
- AUPH 2.0M
- Earning Date
- ICHR 08-04-2025
- AUPH 07-31-2025
- Dividend Yield
- ICHR N/A
- AUPH N/A
- EPS Growth
- ICHR N/A
- AUPH N/A
- EPS
- ICHR N/A
- AUPH 0.27
- Revenue
- ICHR $892,122,000.00
- AUPH $247,295,000.00
- Revenue This Year
- ICHR $14.18
- AUPH $12.15
- Revenue Next Year
- ICHR $6.66
- AUPH $18.34
- P/E Ratio
- ICHR N/A
- AUPH $34.04
- Revenue Growth
- ICHR 13.41
- AUPH 29.20
- 52 Week Low
- ICHR $15.33
- AUPH $5.20
- 52 Week High
- ICHR $42.70
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ICHR 65.37
- AUPH 64.76
- Support Level
- ICHR $21.80
- AUPH $7.36
- Resistance Level
- ICHR $24.12
- AUPH $9.10
- Average True Range (ATR)
- ICHR 1.10
- AUPH 0.45
- MACD
- ICHR 0.35
- AUPH 0.12
- Stochastic Oscillator
- ICHR 81.35
- AUPH 96.69
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.